PGN-EDODM1

Phase 2Small molecule

PPepGen Inc

PGN-EDODM1 is one of 2 small molecule programs targeting Myotonic Dystrophy 1. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myotonic Dystrophy 1Recruiting

Myotonic Dystrophy Type 1Recruiting

Myotonic Dystrophy 1Phase 2

Recruiting

Myotonic Dystrophy Type 1Phase 2

Recruiting

Competition

Competitive Landscape

4 competitors in Myotonic Dystrophy Type 1

#DrugCompanyPhaseTrials

DYNE-101

DDyne Therapeutics

Phase 3

1 2

PGN-EDODM1

PPepGen Inc

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Myotonic Dystrophy 1

NCT06667453

Q1 2029

Phase 2Recruiting

Myotonic Dystrophy Type 1

NCT07220603

Clinical

Trials by Indication[1]

Myotonic Dystrophy Type 12 trials

An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE)

Recruiting·PPepGen Inc·Phase 2·NCT07220603·48 enrolled

Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1

Completed·PPepGen Inc·Phase 1·NCT06204809·24 enrolled

Myotonic Dystrophy 11 trial

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of PGN-EDODM1 in Adult Participants With Myotonic Dystrophy Type 1 (FREEDOM2-DM1)

Recruiting·PPepGen Inc·Phase 2·NCT06667453·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for PGN-EDODM1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PGN-EDODM1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PGN-EDODM1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — PepGen Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PPepGen Inc

PGN-EDODM1

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q1 2029

Trials by Indication[1]

Myotonic Dystrophy Type 12 trials

Myotonic Dystrophy 11 trial

References

Drug Info

Quick Facts

Related News